Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Completed Phase 1 Interventional

Trial of Combination Therapy to Treat COVID-19 Infection

NCT04482686
View directory record Official record
Conditions
COVID, Covid-19, Corona Virus Infection, Coronavirus Infection, Coronavirus-19, SARS-CoV2, SARS-CoV Infection
Interventions
Ivermectin, Doxycycline Hcl, Zinc, Vitamin D3, Vitamin C
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

NCT04405076
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Biological: mRNA-1273, Placebo, mRNA-1273.351
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Savannah, Georgia • Newton, Kansas • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

NCT03549260
View directory record Official record
Conditions
LDL Cholesterol
Interventions
LIB003
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

NCT03750643
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
LY3454738, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
19
States / cities
Anniston, Alabama • North Little Rock, Arkansas • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

NCT06686797
View directory record Official record
Conditions
Healthy
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

NCT03084796
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
CHF 5259, Placebo, Tiotropium Bromide 18 µg Inhalation Capsule
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
112
States / cities
Birmingham, Alabama • Dothan, Alabama • Montgomery, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 24, 2026, 2:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

NCT07225517
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB145, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 24, 2026, 2:33 PM EDT
Terminated Phase 4 Interventional Results available

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

NCT00484718
View directory record Official record
Conditions
Osteoarthritis
Interventions
celecoxib, Oxycodone, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Study of XOMA 3AB

NCT01357213
View directory record Official record
Conditions
Botulism
Interventions
XOMA 3AB, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Results available

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

NCT00715273
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 70 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

NCT01663402
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Alirocumab, Placebo, LMT
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
18,924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
273
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 24, 2026, 2:33 PM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of SAR441236

NCT03705169
View directory record Official record
Conditions
HIV-1-infection
Interventions
SAR441236, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

NCT01188772
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 24, 2026, 2:33 PM EDT
Recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Active Comparator, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets

NCT03432572
View directory record Official record
Conditions
Ureteral Injury
Interventions
Pyridium, Riboflavin, Thiamine
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

NCT00909766
View directory record Official record
Conditions
Obesity
Interventions
BMS-830216, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

NCT02084953
View directory record Official record
Conditions
Hepatitis C
Interventions
BMS-791325, Moxifloxacin, Placebo matching BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

Bosutinib For Autosomal Dominant Polycystic Kidney Disease

NCT01233869
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Bosutinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
20
States / cities
Phoenix, Arizona • Tempe, Arizona • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

NCT06193031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
C16TR, Placebo, Tyvaso®
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 24, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients

NCT00255177
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
VGX-410 (Mifepristone), Placebo
Drug
Lead sponsor
VGX Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
4
States / cities
Farmington, Connecticut • Orlando, Florida • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2009 · Synced Oct 24, 2026, 2:33 PM EDT
Not listed Phase 2 Interventional

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

NCT01202812
View directory record Official record
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2010 · Synced Oct 24, 2026, 2:33 PM EDT
Active, not recruiting Early Phase 1 Interventional

Vaginal Microbiome Exposure and Immune Responses in C-section Infants

NCT03567707
View directory record Official record
Conditions
Allergic Diseases, Asthma
Interventions
Vaginal seeding, Placebo Seeding, Standard care, Post-seeding Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 24, 2026, 2:33 PM EDT
Not listed Not applicable Interventional

Combined Effects of Diabetes Self-Management Education and Nutritional Supplementation on Visual Function and Retinopathy

NCT04120077
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
EyePromise DVS, EyePromise DVS plus EyePromise EZTears
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 24, 2026, 2:33 PM EDT